Page last updated: 2024-10-25

debrisoquin and Glaucoma

debrisoquin has been researched along with Glaucoma in 1 studies

Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Salminen, L1
Lindberg, R1
Toivari, HR1
Huupponen, R1
Kaila, T1
Iisalo, E1

Other Studies

1 other study available for debrisoquin and Glaucoma

ArticleYear
Prevalence of debrisoquine oxidation phenotypes in glaucoma patients.
    International ophthalmology, 1989, Volume: 13, Issue:1-2

    Topics: Cross-Sectional Studies; Debrisoquin; Glaucoma; Glaucoma, Open-Angle; Humans; Isoquinolines; Oxidati

1989